Metagenomi Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Metagenomi Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 3.9 times its market value (net cash). Higher than 98% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 47% in 3 years, but profit fell: $553 less profit per $100 of extra sales. Lower than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-21.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 58% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$553Sales grew 47% in 3 years, but profit fell: $553 less profit per $100 of extra sales.
Lower than 94% of Healthcare companies in United States.
Asset Productivity Ratio
+47% / -47%In 3 years sales changed by +47% while total assets changed by -47%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-14.8×Operating cash was negative last year, while some debt falls due within a year.
Higher than 50% of Healthcare companies in United States.
Cash Cushion Ratio
3.9× cashCash, after subtracting all debt, is 3.9 times its market value (net cash).
Higher than 98% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Metagenomi Therapeutics, Inc. made a loss over the last year. Metagenomi Therapeutics, Inc. owes $0.35 for every $1 it owns. Metagenomi Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMetagenomi Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.27The share price is 0.27 times Metagenomi Therapeutics, Inc.'s book value per share, lower than 97% of Healthcare companies in United States.
Market cap
$31 MThe total market value of all of Metagenomi Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 79% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$113 MWhat Metagenomi Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.98Net worth divided by the number of shares. The share price of $0.82 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-60.6%Metagenomi Therapeutics, Inc. lost 60.6% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
Owes vs Owns
0.35×Metagenomi Therapeutics, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.
Dividend yield
NoneMetagenomi Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-52%Revenue fell 52% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Profit growth
LossMetagenomi Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-348.5%Metagenomi Therapeutics, Inc. lost $349 for every $100 of revenue.
Cash vs debt
Net cashMetagenomi Therapeutics, Inc. held $120 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Metagenomi Therapeutics, Inc.: $31 M ÷ $113 M (30 Jun 2026) = 0.3.
What is Metagenomi Therapeutics, Inc.'s return on equity?
Metagenomi Therapeutics, Inc. lost 60.6% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
How much does Metagenomi Therapeutics, Inc. owe compared with what it owns?
Metagenomi Therapeutics, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.
Does Metagenomi Therapeutics, Inc. pay a dividend?
No. Metagenomi Therapeutics, Inc. does not currently pay a dividend.
Is Metagenomi Therapeutics, Inc.'s revenue growing?
Revenue fell 52% in the year to Dec 2025, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.